Download Full Text (3.4 MB)


Acute Myeloid Leukemia (AML) is a malignancy of the myeloid cell line. Patients diagnosed with AML, typically exhibit symptoms of neutropenia, anemia and thrombocytopenia. The diagnosis of AML is based on greater than 20 percent of myeloid cells in the bone marrow (1). Some risk factors for acquiring the disease include, but not limited to age, sex, smoking, exposure to certain chemicals, radiation, genetic predisposition and being treated with certain chemotherapeutic agents (2).
AML is frequently diagnosed among people between ages 65-74, with a current relative survival rate for AML being 28.7%. Men account for majority of these cases, at a rate of 5.2 per 100,000 persons compared to 3.6 per 100,000 persons for female patients (3).
Our study will assess whether treatment for AML patients has improved after 2015 with the utilization of novel chemotherapeutic agents, particularly for Beaumont Hospital patients.

Publication Date



Acute Myeloid Leukemia


Hematology | Oncology


The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023

Demographics and Survival in AML patients over 60 Years of Age. A Single Institutional Analysi